Takeda places focus on personalized care and innovation for bleeding disorders at ISTH 2022

Takeda places focus on personalized care and innovation for bleeding disorders at ISTH 2022

• 13 abstracts across Takeda’s hematology portfolio and pipeline, including two studies that explore the potential benefits of prophylaxis in patients with von Willebrand disease (VWD) 
• Eight-year readout from the International AHEAD study, a real-world study evaluating long-term outcomes in patients with severe/moderate Hemophilia A  
• Thrombotic thrombocytopenic purpura (TTP) abstract highlights need for more robust, comprehensive epidemiological data to understand global impact of disease. 

CAMBRIDGE, Mass. & OSAKA, Japan, July 9, 2022 – Takeda (TSE: 4502/NYSE:TAK) will present 13 abstracts at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2022, spanning the biopharma leader’s extensive existing hematology portfolio, and R&D pipeline. The data have the potential to drive advances in personalized care for people living with Hemophilia A and VWD, while also highlighting the need for more research to help understand the global impact of rare thrombotic disorders such as TTP. 

“The breadth of data we are presenting across our established portfolio and our pipeline is evidence of our resolve to continually improve the standard of care in and raise disease awareness for bleeding and thrombotic disorders,” said Daniel Curran, M.D., Head, Rare Genetics & Hematology Therapeutic Area Unit at Takeda. “As a patient-driven, science-first organization, we advocate for an individualized approach to treatment: one which acknowledges that each patient’s experience of the disease is unique to them. Several abstracts presented at ISTH add to the growing body of evidence supporting the potential benefits for prophylaxis in VWD and Hemophilia A. In addition, data that are being presented from a systematic review on the epidemiology of TTP further highlights our commitment to facilitating understanding, education, and awareness of rare blood diseases.”    

Takeda is spotlighting data from two studies that explore the potential benefits of prophylaxis when pursuing a patient-centric, individualized approach to treating von Willebrand disease (VWD). Two studies, a post-hoc analysis of a European socio-economic study and a retrospective US cohort study, examined the effects of prophylaxis on disease burden in patients receiving prophylaxis compared to those who were eligible but not currently receiving prophylaxis.i,ii 

An eight-year interim readout from AHEAD – a real-world study evaluating outcomes in patients with severe or moderate hemophilia A – will be featured as an oral presentation.iii The session will discuss data on the impact of pharmacokinetic-guided prophylaxis with FVIII on bleed rates and joint health compared to on-demand treatment.  

Takeda is committed to raising disease awareness and elevating the understanding of rare bleeding and thrombotic disorders. As such, Takeda will present data from a systematic review on the worldwide epidemiology of TTP. This poster presentation highlights the need for more comprehensive, robust data to help understand disease demography and worldwide impact.iv 

A full list of abstracts Takeda is presenting can be found here: https://www.isth2022.org/program.